Biohaven Pharmaceuticals, Inc

Please note: The information displayed on this page might be outdated.
Biohaven Pharmaceuticals, Inc: Commercial-stage, focused on neurological & neuropsychiatric diseases; CGRP receptor antagonist, glutamate modulation, and MPO platforms. NURTEC® ODT approved 1Q20 acute treatment of migraine and 1Q21 preventive treatment of migraine; $136m 3Q21 revenues. Plan to complete enrollment of verdiperstat for the treatment of ALS in 4Q21, and report topline of troriluzole in Spinocerebellar Ataxia in 2H22.
Sector/Industry:
Healthcare/Biotechnology
Characteristics:
Based in...
US - New England
Clinical Stage
Marketed, Phase III
Disease Space
Central Nervous System, Rare Disease
Finance
Revenues
Industry
Biotechnology
Listing
Public, USA
Market Cap
1B +
Therapeutic Modalities
Small Molecule
Website:
http://biohavenpharma.com/
Profiles:
Address:
215 Church Street
New Haven, CT 06510
United States
Presentation:
Please reach out to Solebury Strategic Communications to request a presentation
More info:
Send Message to Request Information
My account:
Log in or register to download presentation, request a 1x1 meeting, view additional roadshows, and more.

Company Participants at Solebury Trout 1x1 Management Access Event 2022

  • Matthew Buten, CFO
  • Vlad Coric, M.D., Chief Executive Officer
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2023 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.